MT4: A Promising Target for Metastasis Therapies (G84560)

Target Name: MT4

NCBI ID: G84560

Content of Review Report on MT4 Target / Biomarker

MT4

MT4: A Promising Target for Metastasis Therapies

MT4 (Metallothionein-IV) is a protein that is synthesized in the liver and has been shown to have a variety of biological functions, including modulating inflammation, protecting cells from oxidative stress, and participating in the detoxification process. Despite its importance, MT4 has not yet been explored as a drug target or biomarker.

In recent years, the study of metastasis has become a major focus in the field of oncology. Metastasis is the process by which cancer cells spread from the primary tumor to other parts of the body, and it is a major contributor to the death rate of cancer patients. Despite its importance, the treatment of metastasis has been limited by the lack of effective therapies.

MT4 has been shown to have a variety of functions that may make it a promising target for metastasis therapies. For example, MT4 has been shown to play a role in the regulation of angiogenesis, the process by which new blood vessels are formed. In addition, MT4 has been shown to modulate the production of extracellular matrix (ECM) proteins, which are involved in the development and maintenance of tissues and organs.

In addition to its functions in metastasis, MT4 has also been shown to have potential as a drug target. For example, MT4 has been shown to play a role in the regulation of inflammation, and it has been shown to have anti-inflammatory effects. In addition, MT4 has been shown to have antioxidant properties, and it has been shown to protect cells from oxidative stress.

Despite its potential as a drug target, MT4 has not yet been explored as such. There are several reasons for this. First, MT4 is a protein that is synthesized in the liver, and it has not yet been shown to interact with small molecules that could be used as drug candidates. Second, MT4 has not yet been shown to interact with other proteins or molecules that have been shown to be involved in metastasis.

In order to explore MT4 as a drug target, researchers will need to conduct studies to determine its interactions with other proteins and molecules. This will involve a combination of techniques, including biochemical, cellular, and animal studies.

In addition to its potential as a drug target, MT4 may also be a valuable biomarker for the diagnosis and treatment of metastasis. For example, MT4 levels have been shown to be elevated in a variety of tissues and conditions, including those associated with cancer. In addition, MT4 has been shown to have potential as a diagnostic biomarker, as it has been shown to be decreased in a variety of cancer tissues and conditions.

Despite its potential as a drug target and biomarker, MT4 has not yet been explored as such. There are several reasons for this. First, MT4 is a protein that is synthesized in the liver, and it has not yet been shown to interact with small molecules that could be used as drug candidates. Second, MT4 has not yet been shown to interact with other proteins or molecules that have been shown to be involved in metastasis.

In order to explore MT4 as a drug target and biomarker, researchers will need to conduct studies to determine its interactions with other proteins and molecules. This will involve a combination of techniques, including biochemical, cellular, and animal studies.

Overall, MT4 is a protein that has not yet been fully explored as a drug target or biomarker. Its potential as a drug target and biomarker makes it an important target for future research. Further studies are needed to determine its interactions with other proteins and molecules, and to explore its potential as a therapy for metastasis.

Protein Name: Metallothionein 4

Functions: Seems to bind zinc and copper. Could play a special role in regulating zinc metabolism during the differentiation of stratified epithelia

The "MT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets